(Cervical Cancer) Cancer Cells Transmitted to Newborns via Amniotic Fluid During Delivery
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- September 20, 2021
- 2 min read
Researchers at Japan's National Cancer Research Center have published a case report in the New England Journal of Medicine describing an unprecedented mode of cancer transmission: cervical cancer cells present in amniotic fluid were transmitted to newborns during vaginal delivery, subsequently causing lung cancer in two boys.
Case Details:
Two boys who developed lung cancer were found to have cancer cells genetically identical to those of their mothers, who had been diagnosed with cervical cancer. Genomic analysis confirmed that the cancer cells originated from the mothers' cervical tumors, transmitted via amniotic fluid during the birth process. This represents the first documented cases of maternal cancer transmission to offspring through this route.
Treatment:
One of the boys was treated with nivolumab (Opdivo), an anti-PD-1 immune checkpoint inhibitor. He achieved a dramatic complete response following nivolumab therapy, with no evidence of residual disease.
Significance:
This report highlights a previously unrecognized risk of vertical cancer transmission during vaginal delivery in mothers with active cervical cancer. The cases also demonstrate the potential efficacy of immune checkpoint inhibitor therapy in pediatric patients with cervical cancer-derived lung tumors.
Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. Please consult your healthcare provider for medical decisions.
Source: New England Journal of Medicine, National Cancer Research Center Japan
Cervical Cancer | Pediatric | Nivolumab | Case Report
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4